At RNAlead, we place biotech innovation at the core of our strategic governance.
Transparent, agile, and driven by deep expertise, our governance reflects a clear ambition: to establish FlashRNA® as the global gold standard in RNA delivery.
The governance model is built on a close collaboration between operational leadership, a highly-motivated scientific team, a committed strategic board and a scientific advisory board covering all of our areas of expertise.
Our management team
Our leadership team brings together diverse, complementary expertise, united by a shared conviction : Biotech innovation must be bold, rigorous, and accessible with a clear focus on solving today’s most pressing therapeutic challenges.
Christine Duthoit
CEO/CSO
PhD scientist with extensive research experience in France (INSERM, CNRS) and the U.S. (St Jude Children’s Research Hospital), Christine has spent 17 years in the biotech industry. She has a strong interest in immunotherapy breakthroughs and spent 16 years at Flash Therapeutics managing gene transfer projects, from cell to in vivo models and finally clinic, as CSO. As the CEO/CSO at RNAlead, she is dedicated to advancing transformative cell and gene therapies thanks to FlashRNA.
Valentin Alsat
COO/CFO
With a strong foundation in finance and a career spanning both industry and biotech, Valentin brings a unique blend of expertise and vision to RNAlead. After starting out in an accounting firm, he turned his skills toward the green energy delivery sector before joining Flash Therapeutics, where he spent five years shaping the company’s financial strategy as Financial Controller and then Finance Director. These experiences, at the crossroads of innovation and growth, have given him the entrepreneurial mindset and leadership needed to drive RNAlead forward as its Managing Director.
Our Scientific Advisory Board
RNAlead is supported by a world-class Scientific Advisory Board composed of leading researchers, clinicians, and industry experts.
Their mission is to help steer the company’s scientific priorities, assess technological advancements, and ensure the continued relevance of our innovation in a rapidly evolving landscape.
Aaron Edwards
Co-Founder and CEO of KiraGen Bio
« RNAlead’s FlashRNA® platform addresses one of the toughest bottlenecks in gene therapy—safe, versatile RNA delivery. Its ability to deliver multiple distinct RNAs simultaneously opens the door to transformative in vivo therapies with enormous long-term potential, while also providing immediate opportunities to improve ex vivo applications like gene editing and cell reprogramming. Having worked with Christine and her team for nearly a decade, I’m confident in their ability to translate this innovation into real clinical impact. »
John De Vos
M.D., PhD. Pr. of Embryology and Regenerative Medicine
« I joined RNAlead’s SAB because I believe RNA delivery technologies, combined with stem cell and genetic engineering approaches, will transform regenerative medicine and bring new therapies to patients. »
Jian Cao
PhD, RAC, Biological CMC, Lycia Therapeutics
« RNAlead’s pioneering FlashRNA@ platform offers a differentiated and highly promising approach to advancing RNA-based therapeutics. The combination of scientific excellence, innovative technology, and a dedicated team convinced me that RNAlead is uniquely positioned to make a significant impact in the field. »
Somebody is coming
in Q1 2026
Our board
Our Supervisory Board brings together key supporters who play an essential role in RNAlead’s journey.
This committee advises and guides the company on critical aspects of development, funding, and industrial partnerships. It is composed of experienced leaders from entrepreneurship, scientific research, pharma, and investment — all committed to sharing their insights to accelerate our growth and impact.
Jacques Rossignol
TechLife Capital Managing Partner and Co-founder
« TechLife Capital, the growth capital fund dedicated to healthcare and technology, is proud to back RNAlead and its experienced and highly competent team. »
Paul Costa De Beauregard
Managing Director of Delphi Invest
« RNAlead delivers RNA safely and efficiently with a proprietary, non-immunogenic technology, tested on a very large number of cell targets, applications and injection route – paving the way for new therapies in immuno-oncology, vaccines, and regenerative medicine. »
Michel Baijot
Chairman White Funds
« RNA delivery is not only about LNP: FlashRNA® technology is the fully owned option developed and accessible by RNAlead for safe and effective RNA delivery. »
Henry Huygues Despointes
TechLife Capital Senior Partner and Co-founder
« RNAlead has a unique technology in RNA delivery, which propose the best of all worlds, and should become the standard of care in RNA-based medicines.«
Our shareholders
« Our investment strategy is based on strong convictions and in-depth investigations of promising companies in Healthcare and Technology. Our role as a catalyst in the transformation of these companies, is helping them grow from European champions to global leaders ».
They trust us
Discover FlashRNA® users
Contact us
Do you have a project in mind? We’d love to hear from you!
